MedGenome Stock

research.medgenome.comHealthcareFounded: 2013

MedGenome is a provider of personalized medicine and genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases. Additionally, MedGenome's wet lab capabilities have allowed for solutions that enable pharma and biotech companies to accelerate early drug discovery pipelines as well as aid biomarker discoveries for companion diagnostics programs.

Register for Details

For more details on financing and valuation for MedGenome, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for MedGenome.

Register Today

MedGenome investors also invested in these private companies


Management Team

Mahesh Pratapneni
Group Chief Executive Officer & Co-Founder, Director
Somasekar Seshagiri
Chief (Genomics and Informatics) & Head (US Operations)
Hiranjith G H
Vice President & Head of Research Services
Dr. V L Ramprasad
Chief Executive Officer - India
Surajit Chakrabartty
Chief Financial Officer

Board Members

Dr. Felix Olale
Sam Santhosh
Neeraj Bhargava
Independent Director
Tejeshwi Sharma
Sequoia Capital

Other companies like MedGenome in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Diagnostics and research startup MedGenome announced on Tuesday it raised $50 million led by life science-focused Novo Holdings, bringing total funding to $185.5 million. MedGenome, a California-based startup, leverages genomic sequencing platforms to aid in diagnostics and drug discovery.